Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production

European Heart Journal

Volumn 34, Issue 32, 2013, Pages 2566-2574

  Colin, Sophie ^a,b,c   Briand, Olivier ^a,b,c   Touche, Véronique ^a,b,c   Wouters, Kristiaan ^a,b,c   Baron, Morgane ^a,b,c   Pattou, François ^a,b   Hanf, Rémy ^d   Tailleux, Anne ^a,b,c   Chinetti, Giulia ^a,b,c   Staels, Bart ^a,b,c   Lestavel, Sophie ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Parc Eurasante Lille Metropole   (France)

Author keywords

Dyslipidaemia; HDL; Intestine; PPAR

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FAT DROPLET; FENOFIBRATE; GFT 505; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; EX VIVO STUDY; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; JEJUNUM BIOPSY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

DYSLIPIDAEMIA; HDL; INTESTINE; PPAR-Α;

ANIMALS; APOLIPOPROTEINS B; BUTYRATES; CACO-2 CELLS; CELLS, CULTURED; CHALCONES; ENTEROCYTES; ESTERIFICATION; FATTY ACIDS; FEMALE; HUMANS; JEJUNUM; LIPOPROTEINS, HDL; MICE; MICE, KNOCKOUT; PHENYLUREA COMPOUNDS; PPAR ALPHA; PROPIONATES;

EID: 84883155218     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs227     Document Type: Article

References (54)

1. Castelli W, Garrison R, Wilson P, Abbott R, Kalousdian S, Kannel W. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-2838. (Pubitemid 17178361)
2. McTaggart F, Jones P. Effects of statins on HDL: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008;22:321-338.
3. Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, CTT C. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
4. Barter P, Gotto A, LaRosa J, Maroni J, Szarek M, Grundy S, Kastelein J, Bittner V, Fruchart J, Treating to New Targets Investigators. HDL-cholesterol, very low levels of LDL-cholesterol, and cardiovascular events. N Engl J Med 2007;357: 1301-1310. (Pubitemid 47481452)
5. Black D. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylo-micron assembly and secretion. Am J Physiol Gastrointest Liver Physiol 2007;293: G519-G524. (Pubitemid 47435377)
6. Su J, Nzekwu M, Cabezas M, Redgrave T, Proctor S. Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest 2009;39:741-754.
7. Green P, Tall A, Glickman R. Rat intestine secretes discoid HDL. J Clin Invest 1978; 61:528-534.
8. Brunham L, Kruit J, Pape T, Parks J, Kuipers F, Hayden M. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006;116:1052-1062.
9. Khabazian B, Ghanbari-Niaki A, Safarzadeh-Golpordesari A, Ebrahimi M, Rahbarizadeh F, Abednazari H. Endurance training enhances ABCA1 expression in rat small intestine. Eur J Appl Physiol 2009;107:351-358.
10. Rachmilewitz D, Fainaru M. ApolipoproteinA-I synthesis and secretion by cultured human intestinal mucosa. Metab Clin Exp 1979;28:739-743. (Pubitemid 9226030)
11. Johansson C, Rössner S, Walldius G. HDL secretion from human intestinal tract. Lancet 1978;8059:324-325.
12. Forman B, Chen J, Evans R. Hypolipidemic drugs, polyunsaturated fatty-acids, and eicosanoids are ligands for PPAR-alpha and delta. Proc Natl Acad Sci USA 1997;94: 4312-4317. (Pubitemid 27194238)
13. Lefebvre P, Chinetti G, Fruchart J, Staels B. Sorting out the roles of PPAR-alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-580. (Pubitemid 43326861)
14. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 1996;137:354-366. (Pubitemid 26005011)
15. Chinetti G, Lestavel S, Bocher V, Remaley A, Neve B, Pineda Torra I, Teissier E, Minnich A, Jaye M, Duverger N, Brewer H, Fruchart J, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53-58. (Pubitemid 32095642)
16. Colin S, Bourguignon E, Boullay A, Tousaint J, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro J, Delerive P. Intestine-specific regulation of PPAR-alpha gene transcription by LXR. Endocrinology 2008;149:5128-5135.
17. Watts G, Barrett P, Ji J, Serone A, Chan D, Croft K, Loehrer F, Johnson A. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003;52:803-811. (Pubitemid 36323589)
18. Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart J, Rubin E, Denèfle P, Staels B, Branellec D. Opposite regulation of human versus mouse apolipoproteinA-I by fibrates in human apolipoproteinA-I transgenic mice. J Clin Invest 1996;97:2408-2416. (Pubitemid 26187327)
19. Hossain M, Tsujita M, Gonzalez F, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 2008; 51:258-266. (Pubitemid 351450604)
20. Chinetti G, Lestavel S, Fruchart J, Clavey V, Staels B. PPAR-alpha reduces cholesterol esterification in macrophages. Circ Res 2003;92:212-217.
21. Chakravarthy M, Lodhi I, Yin L, Malapaka R, Xu H, Turk J, Semenkovich C. Identification of a physiologically relevant endogenous ligand for PPAR-alpha in liver. Cell 2009;138:476-488.
22. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phos-pholipids activate PPAR-alpha in a phospholipase A2-dependent manner. FEBS Lett 2000;471:34-38. (Pubitemid 30173288)
23. Staels B, van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 1992;12:286-294.
24. Bünger M, van den Bosch H, van der Meijde J, Kersten S, Hooiveld G, Müller M. Genome-wide analysis of PPAR-alpha activation in murine small intestine. Physiol Genomics 2007;30:192-204. (Pubitemid 47173282)
25. Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR-alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-2014.
26. Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, Baugé E, Shiri-Sverdlov R, Hofker M, Staels B, Tailleux A. PPAR-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein-E2 knock-in mice. Arterioscler Thromb Vasc Biol 2011;31:1573-1579.
27. Chateau D, Pauquai T, Delers F, Rousset M, Chambaz J, Demignot S. Lipid micelles stimulate the secretion of triglyceride-enriched apolipoprotein-B48- containing lipo-proteins by Caco-2 cells. J Cell Physiol 2005;202:767-776. (Pubitemid 40175852)
28. Béaslas O, Cueille C, Delers F, Chateau D, Chambaz J, Rousset M, Carrière V. Sensing of dietary lipids by enterocytes: a new role for SR-BI/cla-1. PLoS ONE 2009;4:e4271-e4278.
29. Rasband W. Imagej. Bethesda, MD, USA: US National Institutes of Health; 1997-2009 http://rsb.info.nih.gov/ij/.
30. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart J, Staels B, Fiévet C. PPAR-alpha, but not PPAR-gamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterios-cler Thromb Vasc Biol 2005;25:1897-1902. (Pubitemid 41243460)
31. Duval C, Touche V, Tailleux A, Fruchart J, Fievet C, Clavey V, Staels B, Lestavel S. NPC1L1 gene expression is down regulated by LXR activators in the intestine. BBRC 2006;340:1259-1263. (Pubitemid 43083413)
32. Iqbal J, Hussain M. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296:1183-1194.
33. Kimura R, Takahashi N, Murota K, Yamada Y, Niiya S, Kanzaki N, Murakami Y, Moriyama T, Goto T, Kawada T. Activation of PPAR-a suppresses postprandial lipidemia through fatty-acid-oxidation in enterocytes. Biochem Biophys Res Commun 2011;410:1-6.
34. Field F, Watt K, Mathur S. Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the endoplasmic reticulum in Caco-2 cells. J Lipid Res 2007;48:1735-1745. (Pubitemid 47311990)
35. Lee B, Zhu J, Wolins N, Cheng J, Buhman K. Differential association of adipophilin and TIP47 proteins with cytoplasmic lipid droplets in mouse enterocytes during dietary fat absorption. Biochim Biophys Acta 2009;1791:1173-1180.
36. Lee J, Giannikopoulos P, Duncan S, Wang J, Johansen C, Brown J, Plutzky J, Hegele R, Glimcher L, Lee A. The transcription factor cyclic amp-responsive element-binding protein H regulates triglyceride metabolism. Nat Med 2011;17: 812-815.
37. van der Velde A, Brufau G, Groen A. Transintestinal cholesterol efflux. Curr Opin Lipidol 2010;21:167-171.
38. Weingärtner O, Lütjohann D, Böhm M, Laufs U. Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. Atherosclerosis 2010;210:362-365.
39. Xiao C, Lewis G. Regulation of chylomicron production in humans. Biochim Biophys Acta 2011;doi:10.1016/j.bbalip.2011.09.019.
40. Fruchart J, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today 2006;42:39-64.
41. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008;28:1050-1059.
42. Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi Y, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD SI. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the field study): randomised controlled trial. Lancet 2005;366:1849-1861.
43. Tenenbaum A, Motro M, Fisman E, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-1160. (Pubitemid 40720740)
44. The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention study. Circulation 2000;102:21-27.
45. Dullens S, Mensink R, Mariman E, Plat J. Differentiated Caco-2 cells as an in-vitro model to evaluate de-novo apolipoproteinA-I production in the small intestine. Eur J Gastroenterol Hepatol 2009;21:642-649.
46. Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka A, Lepore M, Fruchart J, Clavey V, Ikonen E, Lestavel S, Staels B. PPAR-alpha controls cellular cholesterol trafficking in macrophages. J Lipid Res 2005;46:2717-2725. (Pubitemid 43107484)
47. Pramfalk C, Angelin B, Eriksson M, Parini P. Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells. Biochem Biophys Res Commun 2007;364:402-409. (Pubitemid 350011075)
48. Granneman J, Moore H, Krishnamoorthy R, Rathod M. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 and adipose triglyceride lipase. J Biol Chem 2009;284:34538-34544.
49. Lo V, Erickson B, Thomason-Hughes M, Ko K, Dolinsky V, Nelson R, Lehner R. Arylacetamide deacetylase attenuates fatty-acid-induced triacylglycerol accumulation in rat hepatoma cells. J Lipid Res 2010;51:368-377.
50. Zhou Y, Abidi P, Kim A, Chen W, Huang T, Kraemer F, Liu J. Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceride-mia through enhanced beta-oxidation. Arterioscler Thromb Vasc Biol 2007;27: 2198-2205. (Pubitemid 350287250)
51. Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-2076.
52. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-1506.
53. Lainchbury JG, Troughton RW, Strangman KM, Frampton KM, Pilbrow A, Yandle TG, Hamid AK, Nicholls G, Richards M. N-Terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure. Results from the BATTLE-SCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009;55:53-60.
54. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422-430.